Vivoryon Therapeutics N.V./€VVY
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company specializing in the development of small molecule medicines targeting post-translational modifications implicated in various diseases. Its lead candidate, varoglutamstat, is an oral inhibitor of glutaminyl cyclases (QPCT and QPCTL) with potential applications in inflammatory and fibrotic diseases, neurodegenerative conditions, and cancer. Originally focused on Alzheimer's disease, the company shifted its strategic emphasis to kidney diseases in 2024 after observing significant improvements in kidney function during clinical trials. Headquartered in Halle (Saale) and Munich, Germany, Vivoryon has expanded its intellectual property portfolio, including a U.S. patent granted in May 2025 for varoglutamstat, providing exclusivity through 2044. The company's unique approach centers on modulating disease-related protein activity and stability through targeted enzyme inhibition.
Ticker
€VVY
Sector
Primary listing
AEX
Employees
13
Headquarters
Website
VVY Metrics
BasicAdvanced
€32m
-
-€0.33
1.37
-
Price and volume
Market cap
€32m
Beta
1.37
52-week high
€1.87
52-week low
€1.06
Average daily volume
38k
Financial strength
Current ratio
7.679
Quick ratio
6.753
Long term debt to equity
0.931
Total debt to equity
2.285
Interest coverage (TTM)
-198.04%
Profitability
EBITDA (TTM)
-8.765
Management effectiveness
Return on assets (TTM)
-59.25%
Return on equity (TTM)
-140.45%
Valuation
Price to book
6.7
Price to tangible book (TTM)
8.06
Price to free cash flow (TTM)
-3.556
Free cash flow yield (TTM)
-28.12%
Free cash flow per share (TTM)
-0.314
Growth
Earnings per share change (TTM)
-58.43%
3-year earnings per share growth (CAGR)
-36.33%
10-year earnings per share growth (CAGR)
-16.34%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs